- Investing Ideas
- U.K. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
U.K. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
3
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
3 companies
AstraZeneca
Market Cap: UK£195.9b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£126.28
7D
-5.4%
1Y
22.5%
Haleon
Market Cap: UK£32.6b
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
HLN
UK£3.70
7D
2.7%
1Y
3.1%
hVIVO
Market Cap: UK£47.1m
Operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.
HVO
UK£0.069
7D
-2.1%
1Y
-32.5%